Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients
Study Details
Study Description
Brief Summary
efficacy and safety of Sofosbuvir containing regimens in treatment of COVID-19 Egyptian patients,
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 2/Phase 3 |
Detailed Description
The study aims to assess Sofosbuvir containing regimens in treatment of COVID-19 Egyptian patients,
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Sofosbuvir and Daklatasuvir Sofosbuvir and Daklatasuvir with standard of care treatment |
Drug: Sofosbuvir
Sofosbuvir once daily
Other Names:
Drug: Daclatasvir
daclatasuvir once daily
Other Names:
|
No Intervention: Standard of care treatment Standard of care treatment |
Outcome Measures
Primary Outcome Measures
- Number of patients with improvement or mortality [1 month]
The number of patients with improvement or mortality
Eligibility Criteria
Criteria
Inclusion Criteria:
- COVID 19 positive patients
Exclusion Criteria:
-
COVID-19 patients with critical manifestations.
-
Sepsis.
-
Acute respiratory distress syndrome (ARDS).
-
Decompensated liver disease (Child-Pugh class B or C disease).
-
Chronic renal impairment.
-
Patients with blood diseases (severe anemia, thalassemia, ITP, leukemia ….).
-
Ischemic heart disease within the last 6 months.
-
Chronic pulmonary disease.
-
Malignancy.
-
Pregnancy or breastfeeding.
-
Hypersensitivity to sofosbuvir or ribavirin.
-
Patients with organ transplant.
-
Unwilling to participate in our study
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Cairo and Tanta Universitities | Tanta | Egypt |
Sponsors and Collaborators
- Tanta University
Investigators
- Principal Investigator: Marwa Salama, Lecturer, Tanta University - Faculty of Medicine
- Principal Investigator: sherief Abd-Elsalam, ass. Prof., Tanta University Faculty of medicine
- Principal Investigator: Ahmed Cordie, lecturer, Cairo University
- Principal Investigator: Gamal Esmat, Professor, Cairo University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- Tanta sofosbuvir covid